Viva Biotech Holdings (VBIZF)
0.3434
0.00 (0.00%)
USD |
OTCM |
Feb 06, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 724.45M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 261.5% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 3.149 |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.98% |
Profile
| Viva Biotech Holdings engages in the discovery, development, and manufacturing of clinical drugs. It operates through Drug Discovery, and Contract Development Manufacture Organisation (“CDMO”) and Commercialization segments. The Drug Discovery segment involves in structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage innovative drug development. The Contract Development Manufacture Organisation (“CDMO”) and Commercialization segment consists of contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations. The company was founded by Feng Mao Hua, Chen Cheney Mao and Ying Wu on August 27, 2008 and is headquartered in Shanghai, China. |
| URL | http://www.vivabiotech.com |
| Investor Relations URL | N/A |
| HQ State/Province | Shanghai |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Aug. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 17, 2021 |
Profile
| Viva Biotech Holdings engages in the discovery, development, and manufacturing of clinical drugs. It operates through Drug Discovery, and Contract Development Manufacture Organisation (“CDMO”) and Commercialization segments. The Drug Discovery segment involves in structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage innovative drug development. The Contract Development Manufacture Organisation (“CDMO”) and Commercialization segment consists of contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations. The company was founded by Feng Mao Hua, Chen Cheney Mao and Ying Wu on August 27, 2008 and is headquartered in Shanghai, China. |
| URL | http://www.vivabiotech.com |
| Investor Relations URL | N/A |
| HQ State/Province | Shanghai |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 26, 2026 (est.) |
| Last Earnings Release | Aug. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 17, 2021 |